Davita Inc vs iShares MSCI Australia ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while iShares MSCI Australia ETF trades at $28.27 (market cap $1.19B). The key difference: Davita Inc is far larger — about 9.5× iShares MSCI Australia ETF's market cap, and Davita Inc is more actively traded (650,294 versus 2,714,198). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and iShares MSCI Australia ETF for 63 Days on average.
| DVA | EWA | |
|---|---|---|
Market Cap | $11.28B | $1.19B |
Volume | 650,294 | 2,714,198 |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $30.43 |
52-Week Low | $103.87 | $24.95 |
Typical Hold Time | 113 Days | 63 Days |
Enterprise Value | $24.00B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
The iShares MSCI Australia ETF (EWA) trades at $28.23, down 1.12% amid bearish technical signals and mixed institutional activity. Recent news highlights Australia's stock market hitting three-month lows due to inflation concerns from rising oil prices, though some analysts see upside potential given the country's commodity-driven economy. Technical indicators show selling pressure with moving averages signaling bearish momentum while oscillators remain neutral.
EWA faces near-term headwinds from Australian market volatility and inflation worries, but long-term prospects remain tied to global commodity demand. The ETF's commodity exposure provides diversification benefits, though investors should monitor Australian economic conditions and Federal Reserve policy impacts. Risk-reward appears balanced with technical resistance at $29 and support at $28.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →